NLS Biotech News

Biotech Business – July 10, 2026

Biovica refocuses US strategy and terminates agreement with Tempus AI

Biovica has, by mutual agreement, ended the reference laboratory agreement with Tempus AI, announced in May 2025.

Biotech Business – July 1, 2026

Alzinova signs Letter of Intent with Fujirebio

Alzinova has entered into a non-binding Letter of Intent with Fujirebio, a global provider of in vitro diagnostic solutions, regarding the potential development and commercialization of a blood-based diagnostic test for Alzheimer’s disease based on Alzinova’s Aβ42CC oligomer technology.

Biotech Business – June 30, 2026

Rayca Precision enters partnership with Data Powered Therapeutics

The companies have announced a strategic co-development partnership to design and advance a new generation of nanobody therapeutics for cancers of high unmet need.

Biotech Business – June 29, 2026

Cantargia announces outcome in rights issue

The board of directors of Cantargia has announced the outcome of the rights issue of shares that was announced on 28 May 2026.

Biotech Business – June 23, 2026

Combotope Therapeutics enters into collaboration with Boehringer Ingelheim

The partnership will leverage Combotope’s SMART-Phage platform to generate highly tumor-selective antibodies for next-generation cancer therapies.

Clinical trials

Clinical Trials – July 14, 2026

Evaxion presents new preclinical data for cytomegalovirus vaccine program

Evaxion has presented new data further supporting the multi-component concept of its cytomegalovirus (CMV) vaccine program EVX-V1.

Biotech article – July 13, 2026

New clinical data on the Leqembi subcutaneous autoinjector presented

BioArctic’s partner Eisai has presented new data at the 2026 Alzheimer’s Association International Conference (AAIC), held in London, July 12-15, demonstrating that the Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) formulation offers efficacy and safety comparable to intravenous (IV) administration in people with early Alzheimer’s disease.

Clinical Trials – June 30, 2026

FluoGuide announces positive results from Phase 2 trial

FluoGuide has announced positive results from the first part of its ongoing FG001-CT-005 Phase 2 trial evaluating FG001 for surgical guidance in patients with oral head and neck cancer.

Clinical Trials – June 23, 2026

Elicera receives positive feedback from Swedish MPA on clinical study in Grade IV Glioma

Elicera Therapeutics held a scientific advice meeting with the Swedish Medical Products Agency (MPA) regarding the planned first-in-human clinical study of ELC-401, the company’s iTANK-armed CAR T-cell candidate targeting IL13Ra2 in grade IV glioma.

Clinical Trials – June 18, 2026

Cantargia starts new investigator-initiated lung cancer prevention study

Cantargia has reported that the first patient has been dosed in a Phase 2 clinical trial investigating nadunolimab in up to 59 current or previous smokers with multifocal high-risk lung nodules, and therefore at risk of developing lung cancer.

Clinical Trials – June 15, 2026

Immunovia announces new performance data

Immunovia has announced new performance data for PancreaSure in support of its upcoming Medicare coverage application.

Clinical Trials – June 15, 2026

SynAct announces positive Phase 2b results

SynAct Pharma has reported that resomelagon in combination with methotrexate showed promising clinical effects on par with previous findings with ACR20 reaching 76,4% in the most effective dose compared to 60,8% in the placebo treated control group reaching statistical significance in the subset of patients entering the study with ACR/EULAR class II-III disease.

Clinical Trials – June 11, 2026

Evaxion presents new preclinical data

Evaxion announces new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML). Developed with AI-Immunology, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigens from the dark genome.

Clinical Trials – June 8, 2026

Pharmability submits clinical trial application for first-in-human Phase Ib study

Pharmability has announced the submission of a Clinical Trial Application (CTA) for TIR-C, the company’s lead drug candidate for atopic dermatitis (eczema).

Clinical Trials – May 25, 2026

Sobi announces positive Phase 3 results

Sobi has announced positive topline results from the pivotal Phase 3 REDUCE 2 study evaluating pozdeutinurad (AR882), an investigational next-generation once-daily oral selective URAT1 inhibitor, in adults with gout including those with uncontrolled gout (also referred to as progressive gout) and inadequately controlled by existing therapies.

Profiles in Biotech

Profiles in Biotech – April 23, 2024

Mia Phillipson: Pioneering immunotherapies

Despite being the co-founder of Ilya Pharma and co-director at the Science for Life Laboratory (SciLifeLab), Dr. Mia Phillipson, considers herself a scientist foremost, not an entrepreneur.

Profiles in Biotech – November 28, 2023

Kristian Tryggvason: Reshaping the cell therapy sector

The previous founder and CEO of BioLamina has gone back to business development, and with his new company he aims to redefine cell therapy development even further.

Profiles in Biotech – July 28, 2021

Mathias Uhlén: Driven by curiosity and courage

Being a scientist or an entrepreneur is hard enough. Doing both at the same time sounds like an Olympic sport.

Profiles in Biotech – March 8, 2021

Sara Mangsbo – Scientist and entrepreneur

An academic and an entrepreneur, Dr. Sara Mangsbo, PhD, has found a way to integrate her skills and interests so that they complement and augment her passions.

Profiles in Biotech – January 7, 2021

Evelina Vågesjö: ”I want to see my work go beyond the lab”

What began as a project for Evelina Vågesjö’s doctoral thesis grew into groundbreaking drug candidates and delivery methods, followed not long afterwards, by a clinical-stage biopharmaceutical company.

Profiles in Biotech – October 8, 2020

Robert Langer: Making a difference in medicine

Massachusetts Institute of Technology (MIT) in the US has produced more than its share of engineers and computer scientists, but unlike many of his peers, alumnus Dr. Robert Langer, ScD, turned his chemical engineering skills to medicine, becoming one of the world’s leaders in perfecting effective drug delivery systems.

Profiles in Biotech – June 13, 2018

Britt Meelby Jensen: Accelerating Danish biotech business

She has been called the Danish biotech queen and she is not afraid of responsibility in her role as CEO. On the contrary, Britt Meelby Jensen enjoys leading, setting ambitious goals and accelerating company growth.

Profiles in Biotech – October 6, 2017

Next-generation biotech entrepreneurs

For young scientists and engineers, a startup can be part of early training and education.

Profiles in Biotech – December 16, 2016

Agnete Fredriksen: “You really need to have drive to make it work”

Academia and business don’t always mix, but Agnete B. Fredriksen of Norway has found the formula.

More biotech stories

Biotech Business - June 23, 2026

CHOSA Oncology establishes US presence in Boston

CHOSA Oncology has established a business presence in Boston, Massachusetts, marking an important strategic step in the company's US commercialization for Platin-DRP.

Agreement - June 22, 2026

BioArctic and Lilly sign research and collaboration agreement

The company has entered into the agreement with Eli Lilly and Company regarding a potential new treatment combining BioArctic’s BrainTransporter technology with an undisclosed Lilly drug candidate in neurodegeneration.

Biotech Business - June 18, 2026

Medivir has completed a directed share issue of approx SEK 140 million

The Directed Share Issue was oversubscribed and included both new and existing investors, including Cicero Fonder, Storebrand Sverige Plus and Storebrand Sverige Småbolag Plus as well as Hallberg Management AB, Carl Bennet AB, LINC AB, and Nordea Småbolagsfond Norden.

Biotech Business - June 17, 2026

Alvotech announces USD 152 million share offering

Alvotech has announced the pricing of its previously announced underwritten public offering of 22,666,667 of its ordinary shares at an offering price of USD 3.75 per share.

Biotech Business - June 16, 2026

CEPI extends support for Abera’s development of the BERA vaccine platform

Abera Bioscience has announces that CEPI (Coalition for Epidemic Preparedness Innovations) has decided to extend the ongoing project supporting the development of Abera’s BERA vaccine platform and the company’s innovative influenza vaccine candidate.